Patents by Inventor Konstantin Petrukhin
Konstantin Petrukhin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240245647Abstract: The present disclosure provides a compound having the structure:Type: ApplicationFiled: December 18, 2023Publication date: July 25, 2024Applicants: The Trustees of Columbia University in the City of New York, Albany College of Pharmacy and Health Sciences in the City of Albany, The Board of Regents of the University of OklahomaInventors: Konstantin Petrukhin, Christopher L. Cioffi, Yuhong Wang, Jian-xing Ma, Gennadiy Moiseyev
-
Patent number: 12016853Abstract: Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for the treatment of retinal binding protein (RBP4) related diseases, such as obesity and the like.Type: GrantFiled: April 12, 2021Date of Patent: June 25, 2024Assignees: Belite Bio, Inc, The Trustees of Columbia University in the City of New YorkInventors: Yu-Hsin Tom Lin, Cheng-Chi Irene Wang, Konstantin Petrukhin
-
Patent number: 11980614Abstract: Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for the treatment of retinal binding protein (RBP4) related diseases, such as obesity and the like.Type: GrantFiled: April 12, 2021Date of Patent: May 14, 2024Assignees: Belite Bio, Inc, The Trustees of Columbia University in the City of New YorkInventors: Yu-Hsin Tom Lin, Cheng-Chi Irene Wang, Konstantin Petrukhin
-
Publication number: 20240150297Abstract: The present invention provides a compound having the structure: wherein X1 is N or CR5, wherein R5 is H, OH, halogen or alkyl; X2, X3 and X4 are each independently NH, N, S, O or CR6, wherein each R6 is independently H, OH, halogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, haloalkyl, —O—(alkyl), —S—(alkyl), —NH2, —NH—(alkyl), —N(alkyl)2 or —CO2H; R1, R2, R3 and R4 are each independently —H, —F, —Cl, —Br, —I, —NO2, —CN, —CF3, —CF2H, —OCF3, -(alkyl), -(haloalkyl), -(alkenyl), -(alkynyl), -(aryl), -(heteroaryl), -(cycloalkyl), -(cycloalkylalkyl), -(heteroalkyl), heterocycle, heterocycloalkyl, -(alkylheteroalkyl), -(alkylaryl), —OH, —OAc, —O-(alkyl), —O-(alkenyl), —O-(alkynyl), —O-(aryl), (heteroaryl), —SH, —S-(alkyl), —S-(alkenyl), —S-(alkynyl), —S-(aryl), —S-(heteroaryl), —NH2, —NH-(alkyl), —NH-(alkenyl), —NH-(alkynyl), —NH-(aryl), —NH-(heteroaryl), —C(O)R7, —S(O)R7, —SO2R7, —NHSO2R7, —OC(O)R7, —SC(O)R7, —NHC(O)R7 or —NHC(S)R7, wherein R7 is, H, —(alkyl), —OH, —O(alkyl), —NH2, —NH(alkyl)Type: ApplicationFiled: February 10, 2022Publication date: May 9, 2024Applicants: The Trustees of Columbia University in the City of New York, Albany College of Pharmacy and Health Sciences in the City of AlbanyInventors: Konstantin Petrukhin, Boglarka Racz, Andras Varadi, Christopher : Cioffi, Parthasarathy Muthuraman, Arun Raja
-
Patent number: 11919913Abstract: The present invention provides a compound having the structure: wherein R1, R2, R3, R4, and R5 are each independently H, halogen, CF3 or C1-C4 alkyl; R4 is H, OH, or halogen; B is a substituted or unsubstituted heterobicycle, pyridazine, pyrazole, pyrazine, thiadiazole, or triazole, wherein the heterobicycle is other than chloro substituted indole; and the pyrazole, when substituted, is substituted with other than trifluoromethyl, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: May 13, 2021Date of Patent: March 5, 2024Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Konstantin Petrukhin, Christopher Cioffi, Graham Johnson, Nicoleta Dobri, Emily Freeman, Ping Chen, Michael Conlon, Lei Zhu
-
Publication number: 20230348415Abstract: The present invention provides a compound having the structure: wherein X is CR6 or N; R1, R2, R3, R4, and R6 are each independently —H, —F, —Cl, —Br, —I, —NO2, —CN, —CF3, —CF2H, —OCF3, -(alkyl), -(haloalkyl), -(alkenyl), -(alkynyl), -(aryl), -(heteroaryl), -(cycloalkyl), -(cycloalkylalkyl), -(heteroalkyl), heterocycle, heterocycloalkyl, -(alkylheteroalkyl), -(alkylaryl), —OH, —OAc, —O-(alkyl), —O-(alkenyl), —O-(alkynyl), —O-(aryl), —O-(heteroaryl), —SH, —S-(alkyl), —S-(alkenyl), —S-(alkynyl), —S-(aryl), —S-(heteroaryl), —NH2, —NH-(alkyl), —NH-(alkenyl), —NH-(alkynyl), —NH-(aryl), —NH-(heteroaryl), —C(O)R7, —S(O)R7, —SO2R7, —NHSO2R7, —OC(O)R7, —SC(O)R7, —NHC(O)R8 or —NHC(S) R8, wherein R7 is, H, -(alkyl), —OH, —O(alkyl), —NH2, —NH(alkyl) or —N(alkyl)2, and wherein R8 is, -(alkyl), —O-(alkyl), —NH2, —NH(alkyl) or —N(alkyl)2; Y is O, S, N, NH, or a bond; Z is O, S, N, NH, (CH2)o, or a bond; R5 is H, OH, halogen, alkyl, or R5 is (CH2)p and is bound to Y when Y is N to form a ring together with Z; o andType: ApplicationFiled: July 20, 2021Publication date: November 2, 2023Applicants: The Trustees of Columbia University in the City of New York, Albany College of Pharmacy and Health Sciences in the City of AlbanyInventors: Konstantin Petrukhin, Boglarka Racz, Andras Varadi, Parthasarathy Muthuraman, Arun Raja, Christopher L. Cioffi
-
Publication number: 20230312585Abstract: The present invention provides a compound having the structure: wherein R1, R2, R3, R4, and R5 are each independently H, halogen, CF3 or C1-C4 alkyl, wherein two or more of R1, R2, R3, R4, or R5 are other than H; R6 is H, OH, or halogen; and B is a substituted or unsubstituted heterobicycle, wherein when R1 is CF3, R2 is H, R3 is F, R4 is H, and R5 is H, or R1 is H, R2 is CF3, R3 is H, R4 is CF3, and R5 is H, or R1 is Cl, R2 is H, R3 is H, R4 is F, and R5 is H, or R1 is CF3, R2 is H, R3 is F, R4 is H, and R5 is H, or R1 is CF3, R2 is F, R3 is H, R4 is H, and R5 is H, or R1 is Cl, R2 is F, R3 is H, R4 is H, and R5 is H, then B is other than or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: December 19, 2022Publication date: October 5, 2023Applicant: The Trustees of Columbia University in the City of New YorkInventors: Konstantin Petrukhin, Graham Johnson, Rando Allikmets, Christopher Cioffi, Emily Freeman, Ping Chen, Michael Conlon, Lei Zhu
-
Publication number: 20230241049Abstract: The subject invention provides a method for treating a non-alcoholic fatty liver disease (NAFLD) disease in a subject afflicted therewith comprising administering to the subject a pharmaceutical composition comprising an amount of a compound which is a non-retinoid retinol-binding protein 4 (RBP4) antagonist effective to treat the subject, thereby treating the subject. The subject invention provides a method for treating gout in a subject afflicted therewith comprising administering to the subject a pharmaceutical composition comprising an amount of a compound which is a retinol-binding protein 4 (RBP4) antagonist effective to treat the subject, thereby treating the subject.Type: ApplicationFiled: August 1, 2019Publication date: August 3, 2023Applicant: The Trustees of Columbia University in the City of New YorkInventors: Konstantin Petrukhin, Boglarka Racz, Andras Varadi
-
Patent number: 11649240Abstract: The present invention provides a compound having the structure: wherein R1, R2, R3, R4, and R5 are each independently H, halogen, CF3 or C1-C4 alkyl, wherein two or more of R1, R2, R3, R4, or R5 are other than H; R6 is H, OH, or halogen; and B is a substituted or unsubstituted heterobicycle, wherein when R1 is CF3, R2 is H, R3 is F, R4 is H, and R5 is H, or R1 is H, R2 is CF3, R3 is H, R4 is CF3, and R5 is H, or R1 is Cl, R2 is H, R3 is H, R4 is F, and R5 is H, or R1 is CF3, R2 is H, R3 is F, R4 is H, and R5 is H, or R1 is CF3, R2 is F, R3 is H, R4 is H, and R5 is H, or R1 is Cl, R2 is F, R3 is H, R4 is H, and R5 is H, then B is other than or a pharmaceutically acceptable salt thereof.Type: GrantFiled: November 16, 2020Date of Patent: May 16, 2023Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Konstantin Petrukhin, Christopher Cioffi, Graham Johnson, Rando Allikmets, Emily Freeman, Ping Chen, Michael Conlon, Lei Zhu
-
Publication number: 20210363155Abstract: The present invention provides a compound having the structure: wherein R1, R2, R3, R4, and R5 are each independently H, halogen, CF3 or C1-C4 alkyl; R4 is H, OH, or halogen; B is a substituted or unsubstituted heterobicycle, pyridazine, pyrazole, pyrazine, thiadiazole, or triazole, wherein the heterobicycle is other than chloro substituted indole; and the pyrazole, when substituted, is substituted with other than trifluoromethyl, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: May 13, 2021Publication date: November 25, 2021Applicant: The Trustees of Columbia University in the City of New YorkInventors: Konstantin Petrukhin, Christopher Cioffi, Graham Johnson, Nicoleta Dobri, Emily Freeman, Ping Chen, Michael Conlon, Lei Zhu
-
Publication number: 20210214360Abstract: The present invention provides a compound having the structure: wherein R1, R2, R3, R4, and R5 are each independently H, halogen, CF3 or C1-C4 alkyl, wherein two or more of R1, R2, R3, R4, or R5 are other than H; R6 is H, OH, or halogen; and B is a substituted or unsubstituted heterobicycle, wherein when R1 is CF3, R2 is H, R3 is F, R4 is H, and R5 is H, or R1 is H, R2 is CF3, R3 is H, R4 is CF3, and R5 is H, or R1 is Cl, R2 is H, R3 is H, R4 is F, and R5 is H, or R1 is CF3, R2 is H, R3 is F, R4 is H, and R5 is H, or R1 is CF3, R2 is F, R3 is H, R4 is H, and R5 is H, or R1 is Cl, R2 is F, R3 is H, R4 is H, and R5 is H, then B is other than or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: November 16, 2020Publication date: July 15, 2021Applicant: The Trustees of Columbia University in the City of New YorkInventors: Konstantin Petrukhin, Christopher Cioffi, Graham Johnson, Rando Allikmets, Emily Freeman, Ping Chen, Michael Conlon, Lei Zhu
-
Patent number: 11028098Abstract: The present invention provide a compound having the structure: (structurally represented) wherein R1, R2, R3, R4, and R5 are each independently H, halogen, CF3 or C1-C4 alkyl; R6 is H, OH, or halogen; B is a substituted or unsubstituted heterobicycle, pyridazine, pyrazole, pyrazine, thiadiazole, or triazole, wherein the heterocycle is other than chloro substituted indole; and the pyrazole, when substituted, is substituted with other than trifluoromethyl, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: October 3, 2018Date of Patent: June 8, 2021Assignee: The Trustees of Columbia University in the City of New YorkInventors: Konstantin Petrukhin, Christopher Cioffi, Graham Johnson, Nicoleta Dobri, Emily Freeman, Ping Chen, Michael Conlon, Lei Zhu
-
Patent number: 11000492Abstract: The present invention provides a method for treating or preventing gout in a subject afflicted therewith comprising administering a compound presented or an ester or salt thereof, so as to thereby treat or prevent the gout in the subject.Type: GrantFiled: November 11, 2016Date of Patent: May 11, 2021Assignee: The Trustees of Columbia University in the City of New YorkInventor: Konstantin Petrukhin
-
Publication number: 20210047337Abstract: The present invention provides a compound having the structure: wherein R1, R2, R3, R4, and R5 are each independently H, halogen, CF3, C1-C4 alkyl, aryl or heteroaryl; X is N or CR6, wherein R6 is H, OH, or halogen; A is absent or present, and when present is B has the structure: or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: October 30, 2020Publication date: February 18, 2021Applicant: The Trustees of Columbia University in the City of New YorkInventors: Konstantin Petrukhin, Kirsten Alison Rinderspacher, Shi-Xian Deng, Andras Varadi, Boglarka Racz, Peter Bernstein, Patricia C. Weber, Donald W. Landry, Andrew S. Wasmuth
-
Patent number: 10913746Abstract: The present invention provides a compound having the structure: wherein R1, R2, R3, R4, and R5 are each independently H, halogen, CF3 or C1-C4 alkyl, wherein two or more of R1, R2, R3, R4, or R5 are other than H; R6 is H, OH, or halogen; and B is a substituted or unsubstituted heterobicycle, wherein when R1 is CF3, R2 is H, R3 is F, R4 is H, and R5 is H, or R1 is H, R2 is CF3, R3 is H, R4 is CF3, and R5 is H, or R1 is Cl, R2 is H, R3 is H, R4 is F, and R5 is H, or R1 is CF3, R2 is H, R3 is F, R4 is H, and R5 is H, or R1 is CF3, R2 is F, R3 is H, R4 is H, and R5 is H, or R1 is Cl, R2 is F, R3 is H, R4 is H, and R5 is H, then B is other than or a pharmaceutically acceptable salt thereof.Type: GrantFiled: July 24, 2019Date of Patent: February 9, 2021Assignee: The Trustees of Columbia University in the City of New YorkInventors: Konstantin Petrukhin, Christopher Cioffi, Graham Johnson, Rando Allikmets, Emily Freeman, Ping Chen, Michael Conlon, Lei Zhu
-
Patent number: 10787453Abstract: The present invention provides compounds comprising variously substituted octahydropyrrolopyrroles, their synthesis, methods of making, methods of using, compositions and formulations thereof.Type: GrantFiled: April 11, 2018Date of Patent: September 29, 2020Assignee: The Trustees of Columbia University in the City of New YorkInventors: Konstantin Petrukhin, Christopher Cioffi, Graham Johnson, Nicoleta Dobri, Emily Freeman, Ping Chen, Michael Conlon, Lei Zhu
-
Publication number: 20200246289Abstract: The present invention provides a method for treating or preventing gout in a subject afflicted therewith comprising administering a compound presented or an ester or salt thereof, so as to thereby treat or prevent the gout in the subject.Type: ApplicationFiled: November 11, 2016Publication date: August 6, 2020Applicant: The Trustees of Columbia University in the City of New YorkInventor: Konstantin Petrukhin
-
Patent number: 10570148Abstract: The present invention provides a compound having the structure: (structurally represented) wherein R1, R2, R3, R4, and R5 are each independently H, halogen, CF3 or C1-C4 alkyl; R6 is alkyl; A is absent or present, and when present is —C(O)— or —C(O)NH—; B is substituted or unsubstituted monocycle, bicycle, heteromonocycle, heterobicycle, benzyl, CO2H or (C1-C4 alkyl)-CO2H, wherein when B is CO2H, then A is present and is —C(O)—, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: April 3, 2018Date of Patent: February 25, 2020Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Konstantin Petrukhin, Christopher Cioffi, Graham Johnson, Nicoleta Dobri, Emily Freeman, Ping Chen, Michael Conlon, Lei Zhu
-
Publication number: 20190382409Abstract: The present invention provides a compound having the structure: wherein R1, R2, R3, R4, and R5 are each independently H, halogen, CF3 or C1-C4 alkyl, wherein two or more of R1, R2, R3, R4, or R5 are other than H; R6 is H, OH, or halogen; and B is a substituted or unsubstituted heterobicycle, wherein when R1 is CF3, R2 is H, R3 is F, R4 is H, and R5 is H, or R1 is H, R2 is CF3, R3 is H, R4 is CF3, and R5 is H, or R1 is Cl, R2 is H, R3 is H, R4 is F, and R5 is H, or R1 is CF3, R2 is H, R3 is F, R4 is H, and R5 is H, or R1 is CF3, R2 is F, R3 is H, R4 is H, and R5 is H, or R1 is Cl, R2 is F, R3 is H, R4 is H, and R5 is H, then B is other than or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: July 24, 2019Publication date: December 19, 2019Applicant: The Trustees of Columbia University in the City of New YorkInventors: Konstantin Petrukhin, Christopher Cioffi, Graham Johnson, Rando Allikmets, Emily Freeman, Ping Chen, Michael Conlon, Lei Zhu
-
Patent number: 10421720Abstract: The present invention provides Octahydrocyclopentapyrrole compounds having the structure: (structurally represented) wherein psi is absent or present, and when present is a bond; R1, R2, R3, R4, and R5 are each independently H, halogen, CF, or C1-C4 alkyl; R6 is absent or present, and when present is H, OH, or halogen; A is absent or present, and when present is C(O) or C(O)NH; B is substituted or unsubstituted monocycle, bicycle, heteromonocycle, heterobicycle, benzyl, CO2H or (C1-C4 alkyl)-CO2H, wherein when B is CO2H, then A is present and is C(O); and when psi is present, then R6 is absent and when psi is absent, then R6 is present, or a pharmaceutically acceptable salt thereof, for treatment of diseases characterized by excessive lipofuscin accumulation in the retina.Type: GrantFiled: March 26, 2018Date of Patent: September 24, 2019Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Konstantin Petrukhin, Christopher Cioffi, Graham Johnson, Nicoleta Dobri, Emily Freeman, Ping Chen, Michael Conlon, Lei Zhu